Regulatory Story
Go to market news section View chart   Print
Eco Animal Health  -  EAH   

Final Results

Released 07:00 30-Jun-2017

Final Results

LONDON--(BUSINESS WIRE)--

30 June 2017

ECO Animal Health Group plc (‘’ECO”)

(AIM: EAH)

Results for the year ended 31 March 2017

ECO ANIMAL HEALTH REPORTS ANOTHER STRONG PERFORMANCE

HIGHLIGHTS

Financials

Operations

Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:

ECO has started the current year strongly with revenue ahead of the previous year. The ongoing weakness in the value of sterling may continue to be of benefit to ECO as virtually all our sales and the majority of costs arise locally in dollars, RMB or the euro. The business is robust with a sound, debt free balance sheet and this coupled with our strong cash generation will allow us to capitalise on market opportunities as they arise. We look forward with confidence.”

“The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations.”

Contacts:

ECO Animal Health Group plc      
Peter Lawrence 020 8336 6190
Marc Loomes 020 8447 6906
 
Spiro Financial
Anthony Spiro 020 8336 6196
 
Peel Hunt LLP (Nominated Adviser)
Dan Webster, Adrian Trimmings, George Sellar 020 7418 8900
 
N+1 Singer (Joint Broker)
Mark Taylor, Brough Ransom 020 7496 3000
 

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

CHAIRMAN’S STATEMENT

FOR THE YEAR ENDED 31 MARCH 2017

I am very pleased to report that ECO Animal Health Group has delivered another record set of results. It is particularly encouraging for our shareholders that ECO’s strong trading performance has been reflected in the company’s market capitalisation, which is now close to £400 million.

ECO operates in a market segment that provides essential medications to the global animal protein production industry, which seeks to meet an ever growing demand. The World Health Organisation predicted in 2014 that the demand for meat protein for human consumption would double by 2050. ECO’s treatments, when used under strict veterinary supervision, help ensure animal health, welfare and food safety.

The company’s patented flagship molecule, Aivlosin®, is used for the treatment of economically important diseases of pigs and poultry, amongst the two largest growing segments of this vital industry. Aivlosin® is prescribed under veterinary control for the short duration treatment of diagnosed diseases at low, yet efficacious, dose rates with a zero day or very short drug withholding period. The overall and desired beneficial effect is to reduce the level of antibiotics used in the production of food of animal origin. This plays directly to the demands of consumers and the regulatory authorities.

Highlights of the year include new drug registrations for both pigs and poultry in different parts of the globe and upon which ECO will be able to capitalise with expanding sales. It is also helpful for us that worldwide action to ban antibiotic growth promoters and the desire to reduce the amount of antimicrobials used in global farming, has promoted Aivlosin®, our patented medication.

As the global animal health industry continues to consolidate, we are actively seeking to acquire drugs that fit comfortably in our portfolio and serve the specialised markets that we serve. Our ability to generate cash, together with our cash balances, places ECO in a strong position to take advantage of any opportunity that may arise.

Financial Performance

Pre tax profit advanced by 75 per cent to a record £13.5 million (2016: £7.7m) and earnings per share advanced to 16.35 pence per share (2016: 9.71 pence). Sales for the year rose 30 per cent to £61.4m (2016: £47.1m). Earnings before interest, tax, depreciation, amortisation, non-controlling (minority) interests, foreign exchange and share based payments, (EBITDA), increased by 54 per cent to almost £17.1 m (2016: £11.1m). Cash generated from operations rose to £13.1m, some of which was invested in our planned expansion in technology, research and development and stock holding. Gross profit advanced by 44 per cent to £30.3 million (2016: £21m) as margins increased, reflecting a stronger product and geographic mix, as well as the short term benefit arising from holding six months’ inventory on the day of the UK’s decision to leave the EU.

The board is pleased to declare an interim dividend of 4.6 pence per share to be paid on October 6 to shareholders on the register on 15 September 2017. The total dividend for the year of 7.1 pence per share is 25 per cent above the level of last year (2016: 5.7 pence) and reflects the board’s continued confidence in the business and its long stated desire to implement a progressive dividend policy.

Marketing and Development

ECO currently holds several hundred marketing authorisations around the globe and sells in almost sixty countries. The company is now realising the commercial benefit from this ongoing investment, currently totalling almost £68m, in the intellectual property inherent in both Aivlosin® and its other products and our focus is to capitalise on the sales potential of these assets.

The benefit to ECO of such a high investment cost and the lengthy time scale associated with obtaining marketing authorisations is the barrier to entry it creates for potential competition.

In June 2016, ECO received a marketing authorisation from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption. This treatment has a zero drug withdrawal period, which means that the eggs can still be collected from treated and recovering laying birds and sent straight to market. This approval, an important step in the development of Aivlosin® for commercial layers, enables ECO to accelerate the submission of the Aivlosin® regulatory files for the treatment of layers in the key global egg producing markets. Approvals have been obtained in Mexico, the world’s fourth largest egg producing country and Thailand and Malaysia (after the period end), both global top twenty egg producing countries. These licenses, once Aivlosin® is approved for commercial layers in the key global egg producing markets, have the potential to generate significant earnings.

In December 2016, ECO received a marketing authorisation from the Brazilian Ministry of Agriculture, Livestock and Supply (MAPA) for the use of Aivlosin® 625 mg/g water soluble granules for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease of swine. Brazil is one of the world’s leading producers and exporters of pork and this new formulation enhances our ability to offer an expanded range of valuable therapeutic tools to swine producers for both the domestic and export markets.

We have continued to make significant investments in our product development project pipeline. This includes the roll out of existing approvals into new geographies, new disease indications for pigs and poultry and new species, all of which should offer continuing growth opportunities for sales of our patented medication.

Operations

Worldwide revenue grew impressively, the third year in succession that it has advanced by over 20 per cent. There were strong performances in all major territories. Sales of Aivlosin®, our flagship product, increased by more than 27 per cent compared with the same period last year. Sales of Ecomectin ®, our range of differentiated antiparasistic formulations for ruminants, pigs and horses and the other products in the portfolio also grew strongly.

Sales of Aivlosin® in North America, a region that accounts for more than one third of its potential market, continue to develop strongly while in Canada, sales have started to stabilise following an extraordinarily successful launch. The approval received just before the start of the year for Aivlosin® Type A Medicated Article (or Premix) formulation for swine in the United States, with a zero withdrawal period, has enabled us to build on the excellent start that we have made in this key market.

In China, our subsidiary, Zhejiang ECO Biok Animal Health Products, which was established over a decade ago, had another successful year. Sales were driven by the ongoing high price of pork, which resulted in an increased investment by producers in high value breeding stock with a focus on the health of these animals and a reduction in the ‘backyard’ production of pork.

Revenue in Southeast Asia continued to grow, benefiting from our renewed strategic focus on this region.

In Latin America, our subsidiary in Mexico continued to demonstrate very good growth, despite the difficult economic and political climate in that country, while Brazil had a difficult year, reflecting the turbulent economic and political climate. We have taken the necessary structural measures to ensure when the recovery occurs, we are well positioned to capitalise on the opportunities.

In Europe, there was encouraging growth in the UK, in Eastern Europe, (notably Poland and Russia) and in Turkey.

People

On behalf of all investors I would like to thank our staff worldwide, now numbering close to 200, for their individual and collective contribution to our results. Their conscientiousness and hard work will enable ECO to face the future with confidence.

Outlook

ECO has started the current year strongly, maintaining the record growth of recent years. The ongoing weakness in the value of sterling may continue to be of benefit to ECO as virtually all our sales and the majority of costs arise locally in dollars, RMB or the euro. The business continues to be strongly cash generative and debt free, which should enable us to capitalise on any market opportunities that present themselves. We look forward with confidence.

Peter A Lawrence

Chairman

29 June 2017

STRATEGIC REPORT

FOR THE YEAR ENDED 31 MARCH 2017

Financial

Group sales in the year to 31 March 2017 rose by over 30% to £61.4m. Sales of our flagship, patented, therapeutic (disease treating) drug, Aivlosin®, also rose by over 27% in sterling compared to the previous year. Margins also substantially improved.

EBITDA (Earnings before interest, tax, depreciation, amortisation and impairment, share based payments, foreign exchange movements and non-controlling (minorities) interests is our main key performance indicator because we are required to amortise our drug registration costs even though we believe they are increasing in value and this figure increased over 54% to almost £17.1m, another new record for the company. Pre-tax profit increased by almost 75% to £13.5m.

Group cash at the year end was £20.6m. Inventories were intentionally higher than last year, which ensures continuity of supply of key products.

Key Performance Indicators

The key performance indicators (‘KPIs’) for the Group are those that communicate the financial performance and strength of the group as a whole to shareholders.

A summary of the KPI’s is as follows:

Financial   2017   2016   2015
 
Revenue £m 61.4 47.1 39.0
Gross Profit £m 30.3 21.0 17.5
Gross Margin % 49.4 44.6 44.7
EBITDA £m 17.1 11.1 8.60
Cash balances, net of borrowing £m 20.6 15.7 17.7
Non Financial
Health and Safety - major accidents reported to the board in the year Nil Nil Nil
 

Currency

Under IFRS rules, financial assets at the period end are translated from foreign currencies using the period end exchange rates. It has been our practice not to convert the majority of the currency balances into sterling, but to use them to pay overseas suppliers in local currency and invest in the business.

Risks and Uncertainties

All businesses face a number of strategic and operational risks and uncertainties and the Board considers that the following could influence the Group’s performance:

Currency Movements

The Group exports its products to almost 60 countries and is exposed to movements in currency. It has not been the company’s practice to convert currencies which are used for purchasing raw materials and services in those currencies and this acts as an extensive hedge against currency fluctuations.

Commercial Risks

There is increasing pressure on veterinarians to prescribe medications appropriately and in accordance with the product label. Aivlosin® meets all current guidelines for the judicious and prudent use of antimicrobials for food producing animals and is never used in human health. The Group spends considerable effort and resource liaising with regulatory authorities and leading consultants to ensure that it remains compliant with all prescribing guidelines.

Supply Risks

The Group is dependent on a small number of suppliers for some of its raw materials and maintains business interruption insurance in respect of each of these. In the longer term the Group continues to build strategic manufacturing partnerships internationally and has increased safety stock levels in order to protect its complex global supply chain.

Dependence on key customers

The Group is dependent on a number of customers and distributors in each of the territories into which it sells. The loss of one or more of its key customers could result in lower than expected sales and have a significant impact on the scale of its operations. The Group seeks to minimise reliance on key territories and individual customers and distributors by expanding its sales base to new regions of the world, most recently by increasing its presence in South East Asia, a process which is set to continue.

Disease

Although outbreaks of diseases for which our products are indicated are generally beneficial to our sales, some disease outbreaks temporarily impact on production, disrupt the free movement of animals and affect trade. In the face of continued global demand for animal protein, however, any reduction in supply leads to increased prices and therefore benefits those who have taken effective measures to prevent or control the disease. In the medium term, most disease outbreaks are generally well controlled by appropriate intervention strategies.

Timing of approval of marketing authorisations

Aivlosin® has been licenced for use in pigs and/or in poultry by Europe, the USA, Canada, Japan, China and by many other regulatory bodies globally but the exact timing of new approvals of marketing authorisations is difficult to predict. Regulatory authorities may submit additional questions or require supplementary trial work to be performed prior to granting of a license and this can lead to some delay. Therefore, considerable resource is devoted to our licensing work in order to address any issues that may arise in as timely a manner as is possible.

Dependence on key personnel

The Group is dependent on a relatively small number of key personnel for a company of its size and the loss of one or two of these personnel would be likely to have a detrimental impact on the business. Management intend to review the situation in the current year and will make appointments to mitigate this risk where appropriate and where suitable candidates can be found.

Strategy

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. The company has developed into a significant UK based business with subsidiaries, joint operation and distributors in almost 60 countries. ECO has been granted over 600 drug registrations around the world for its pharmaceutical products, which are principally, but not exclusively, for the treatment of various conditions in pigs and poultry. The company uses advanced science in order to offer a wide and effective range of specialist treatments, underpinned by strong customer service.

The company will continue to pursue organic growth by developing its markets and expanding its customer base. It will also continue to research and develop additional applications for its established and proven ranges of active pharmaceutical ingredients including new species. ECO will also consider acquisition opportunities as they arise, provided they meet its market, financial and strategic objectives.

Post balance sheet event

The Company paid a dividend of £1,635,000 on 7th April 2017 to its shareholders.

Trading update and outlook

The current year has started well with continued growth and particularly good demand from customers in North America, Mexico and Japan. It is particularly pleasing to note the first signs of a recovery in Brazil. It is expected that sales in this market will be further enhanced by the appointment of a new distributor after the year end. The weak pound is largely beneficial for our business, as very few of the group sales are in sterling.

Peter Lawrence

Chairman

29 June 2017

CORPORATE GOVERNANCE

FOR THE YEAR ENDED 31 MARCH 2017

Principles of Corporate Governance

The Company’s shares are admitted to trading on the AIM market of the London Stock Exchange and the Company is therefore not required to report on compliance with the UK Corporate Governance Code. However, the Directors support the UK Corporate Governance Code and are implementing many of the recommendations which are relevant to a business of the size of Eco Animal Health Group plc. The Board is committed to high standards of corporate governance.

The Board

At the 31st March 2017, the Board comprised of two Non-Executive Directors and five Executive Directors.

The composition of the board of directors as well as Directors’ biographies can be found on our website www.ecoanimalhealthgroupplc.com under the section “About the Company” and then “Directors”.

The full Board is responsible and accountable to the shareholders for the management and success of the Company and provides effective controls to assess and manage the risks in the Company.

The Board meets at least once a quarter to review the operational and financial performance of the Company and to determine and monitor the Company’s strategy and to ensure that the necessary resources are in place to meet the Company’s objectives. The Board members each receive an agenda prior to the meeting and the Financial Director prepares a financial pack which is distributed to the Directors every month.

The roles of the Chief Executive Officer and Executive Chairman are well defined and clearly separated. The Chairman oversees the Board’s work, ensures the Board’s decision-making is balanced and that the Non-Executive Directors have all the relevant information on matters to be decided and discussed. The Chief Executive Officer is responsible for implementing the strategy of the Board and managing the day to day business activities of the Company.

All Directors are subject to reappointment by shareholders at the first Annual General Meeting following their appointment and thereafter by rotation. The Board considers that it has sufficient independence and that both of the Non-Executive Directors are of sufficient competence and calibre to add strength and objectivity to the Board.

The Board delegates its authority for certain matters to its Audit and Remuneration Committees, details of which can be found on our website at www.ecoanimalhealthgroupplc.com/investor-relations/rule-26.aspx .

The Audit Committee

Throughout the financial year, the committee comprised of two Non-Executive Directors, Mr Anthony Rawlinson ACA BA (Hons) as Chairman and Mr David Danson BVSc MRCVS and meets at least twice each financial year with the external auditors and considers any issues that are identified during the course of the audit work. The Board is satisfied that the Committee members have both recent and relevant experience.

In the year ended 31 March 2017 and up to the date of this report, the actions taken by the Audit Committee to discharge its duties included:

The Remuneration Committee

In view of the size of the Board, the duties and responsibilities of the remuneration committee have been assumed by the Board as a whole. The Board expects this situation to continue for the foreseeable future until further development of the business gives rise to the appointment of one or more additional directors.

The table below sets out the Directors’ attendance at Board and Committee meetings held during the year to 31 March 2017.

  Board of Directors and  

 

Remuneration Committee

Audit Committee

(4 Meetings held) (2 meetings held)
Eligible   Attended Eligible   Attended
Peter Lawrence 4 4 - -
Marc Loomes 4 4 - -
Kevin Stockdale 4 3 - -
Julia Trouse 4 4 - -
Brett Clemo 4 4 - -
David Danson 4 4 2 2
Anthony Rawlinson 4 4 2 2
 

Relations with Shareholders

The Board recognizes the importance of communication with its shareholders. The Group maintains an informative website at www.ecoanimalhealthgroupplc.com .Copies of the Annual Report and financial statements are issued to all shareholders who have requested hard copies and electronic copies are available on the Group’s website. The Group also uses its website to provide information likely to be of interest to shareholders and other interested parties. The Company Secretary, Mrs Julia Trouse, also deals with correspondence as and when it arises throughout the year.

Following the announcement of the Company’s half year and full year results the Chairman, the Chief Executive Officer and other Directors, although usually only two, make detailed presentations to institutional shareholders and investment analysts.

The Board encourages shareholder participation at its Annual General Meeting, where shareholders may ask questions and can be updated on the Group’s activities and strategies, which are already in the public domain.

Internal control

The Board is ultimately responsible for the Group’s system of internal controls and for reviewing its effectiveness throughout the year. The system is designed to manage rather than eliminate the risk of failure to achieve the Group’s strategic objectives and can only provide reasonable and not absolute assurance against material misstatement or loss.

The Board monitors financial controls through the setting and approval of an annual budget and the regular review of monthly management accounts. Management accounts contain a number of indicators that are designed to reduce the possibility of misstatement in the financial statements.

The Group has in place defined authorisation levels for expenditure, the placing of orders and signing authorities. The daily cash movements of the Group are reconciled and monitored by the finance department and circulated to the Directors daily and the Group’s cash flow is monitored.

The Board maintains a continuous process for identifying, evaluating and managing significant risks across the Group together with a comprehensive annual review of risks which covers both financial and non-financial areas.

Where the management of operational risk requires outside advice, this is sought from expert consultants.

Going concern

At the balance sheet date the Group had cash balances of £20.6 million and no borrowings. Since the year end the Group has continued to trade profitably and to generate cash. The Board considers that the Group has sufficient cash to meet its current and future liabilities when they fall due and that the Company and the Group have sufficient resources available to continue operating in the foreseeable future. Future uses of the cash are monitored against known and authorised budget expenses for the Company’s planned growth and expansion. For this reason, the going concern basis continues to be adopted in preparing the financial statements.

By order of the Board

Julia Trouse

Company Secretary

29 June 2017

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED 31 MARCH 2017

    2017       2016
Notes £000's £000's
 
Revenue 2,3 61,422 47,138
Cost of sales (31,103) (26,109)
 
Gross profit 30,319 21,029
 
Other income 4 379 337
Administrative expenses (18,053) (13,918)
 
Profit from operating activities 5 12,645 7,448
 
Finance income 6 784 208
Finance costs 6 - (7)
Net finance income 784 201
 
Share of profit of associate 14 23 25
Reversal of impairment of associate 14 - 30
23 55
 
 
Profit before income tax 13,452 7,704
Income tax (charge) 8 (1,453) (995)
Profit for the year 11,999 6,709
 
 
Profit attributable to:
Owners of the parent company 10,565 6,037
Non-controlling interest 24 1,434 672
Profit for the year 11,999 6,709
 
   
Earnings per share (pence) 7 16.35 9.71
   
Diluted earnings per share (pence) 7 16.17 9.56
 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 MARCH 2017

    2017       2016
Notes £000's £000's
 
Profit for the year 11,999 6,709
 

Other comprehensive income (net of related tax effects):

Items that will or may be reclassified to profit/(loss) in future periods:

 
Foreign currency translation differences 1,030 (198)
Items that will not be reclassified:
Defined benefit plan actuarial (losses)/gains 21 (483) 27
Revaluation of property - 108
Deferred tax on revaluations 10 (22)
Other comprehensive income for the year 557 (85)
 
Total comprehensive income for the year 12,556 6,624
 
Attributable to:
Owners of the parent company 10,829 6,049
Non-controlling interest 24 1,727 575
12,556 6,624
 

All items listed in other comprehensive income have gone through reserves and are shown in the consolidated statement of changes in equity.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2017

CONSOLIDATED   Attributable to the owners of the Parent          
Share   Share   Treasury   Revaluation Other Retained Total Non-controlling Total
Capital Premium Reserve Reserve Reserves Earnings Interest Equity
Account
£000's £000's £000's £000's £000's £000's £000's £000's £000's
 
Balance as at 31 March 2015 3,157 54,198 (5,217) 568 1,775 18,771 73,252 3,029 76,281
 
Profit for the year - - - - - 6,037 6,037 672 6,709
Other comprehensive income:
Foreign currency differences - - - - - (101) (101) (97) (198)
Actuarial gains on pension scheme assets - - - - - 27 27 - 27
Revaluation of investment property - - - 108 - - 108 - 108
Deferred taxation -   -   -   (22)   -   -   (22)   -   (22)
Total comprehensive income for the year -   -   -   86   -   5,963   6,049   575   6,624
 
Transactions with owners recorded directly in equity
Contributions by and distributions to owners
Movement in Treasury Reserve arising from disposal of jointly owned shares - - 4,073 - - - 4,073 - 4,073
Issue of shares in the year 48 1,392 - - - - 1,440 - 1,440
Purchase of shares into treasury - - - - - (43) (43) - (43)
Share-based payments - - - - 326 - 326 - 326
Transfers on expiry of options - - - - (73) 73 - - -
Dividends relating to 2015 -   -   -   -   -   (2,940)   (2,940)   (402)   (3,342)
Transactions with owners recorded directly in equity 48   1,392   4,073   -   253   (2,910)   2,856   (402)   2,454
Balance as at 31 March 2016 3,205 55,590 (1,144) 654 2,028 21,824 82,157 3,202 85,359
 
Profit for the year - - - - - 10,565 10,565 1,434 11,999
Other comprehensive income:
Foreign currency differences - - - - - 737 737 293 1,030
Actuarial (losses) on pension scheme assets - - - - - (483) (483) - (483)
Deferred taxation change in rate -   -   -   10   -   -   10   -   10
Total comprehensive income for the year -   -   -   10   -   10,819   10,829   1,727   12,556
Transactions with owners recorded directly in equity
Contributions by and distributions to owners
Movement in Treasury Reserve arising from disposal of jointly owned shares - - 1,144 - - - 1,144 - 1,144
Issue of shares in the year 66 2,517 - - - - 2,583 - 2,583
Sale of treasury shares - 47 - - - 60 107 - 107
Share-based payments - - - - 678 - 678 - 678
Transfers on expiry of options - - - - (257) 257 - - -
Dividends relating to 2016 -   -   -   -   -   (3,667)   (3,667)   (587)   (4,254)
Transactions with owners 66   2,564   1,144   -   421   (3,350)   845   (587)   258
Balance as at 31 March 2017 3,271   58,154   -   664   2,449   29,293   93,831   4,342   98,173
 

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2017

COMPANY              
Share Share Treasury Revaluation Other Retained Total
Capital Premium Reserve Reserve Reserves Earnings
Account
£000's £000's £000's £000's £000's £000's £000's
 
Balance as at 31 March 2015 3,157 54,198 (5,217) 299 1,775 12,865 67,077
 
Profit for the year - - - - - 91 91
Other comprehensive income:
 
Actuarial gains on pension scheme assets - - - - - 27 27
Revaluation of investment property - - - 108 - - 108
Deferred taxation -   -   -   (22)   -   -   (22)
Total comprehensive income for the year -   -   -   86   -   118   204
 
Transactions with owners recorded directly in equity
Contributions by and distributions to owners
 
Issue of shares in the year 48 1,392 - - - - 1,440

Movement in Treasury Reserve arising from
disposal of jointly owned shares

- - 4,073 - - - 4,073
Share-based payments - - - - 326 - 326
Purchase of shares into treasury - - - - - (43) (43)
Transfers on expiry of options - - - - (73) 73 -
Dividends relating to 2015 -   -   -   -   -   (2,940)   (2,940)
Transactions with owners 48   1,392   4,073   -   253   (2,910)   2,856
Balance as at 31 March 2016 3,205 55,590 (1,144) 385 2,028 10,073 70,137
 
Profit for the year - - - - - 5,144 5,144
Other comprehensive income:
Actuarial (losses) on pension scheme assets - - - - - (483) (483)
Deferred taxation change in rate -   -   -   10   -   -   10
Total comprehensive income for the year -   -   -   10   -   4,661   4,671
 
Transactions with owners recorded directly in equity
Contributions by and distributions to owners
Issue of shares in the year 66 2,517 - - - - 2,583

Movement in Treasury Reserve arising from
disposal of jointly owned shares

- - 1,144 - - - 1,144
Share-based payments - - - - 678 - 678
Sale of treasury shares - 47 - - - 60 107
Transfers on expiry of options - - - - (257) 257 -
Dividends relating to 2016 -   -   -   -   -   (3,667)   (3,667)
Transactions with owners 66   2,564   1,144   -   421   (3,350)   845
Balance as at 31 March 2017 3,271   58,154   -   395   2,449   11,384   75,653
 

STATEMENTS OF FINANCIAL POSITION (CO. NUMBER: 01818170)

AS AT 31 MARCH 2017

    Group     Company  
2017 2016 2017 2016
Notes £000's £000's £000's £000's
Non-current assets
Intangible assets 11 53,883 49,337 - -
Property, plant and equipment 12 1,865 1,833 731 738
Investment property 13 185 185 185 185
Investments 14 97   64   20,082   20,082
56,030 51,419 20,998 21,005
Current assets
Inventories 15 19,675 15,593 - 925
Trade and other receivables 16 16,158 13,629 46,132 41,409
Income tax recoverable 395 140 - -
Other taxes and social security 897 517 694 309
Cash and cash equivalents 18 20,602   15,665   8,684   7,109
 
Total current assets 57,727 45,544 55,510 49,752
 
Liabilities
Trade and other payables 19 (13,733) (10,373) (526) (229)
Income tax (238) (280) - -
Other taxes and social security (447) (240) (103) (156)
Dividends (39)   (38)   (39)   (38)
Current liabilities (14,457)   (10,931)   (668)   (423)
Net current assets 43,270   34,613   54,842   49,329
Total assets less current liabilities 99,300 86,032 75,840 70,334
 
Non current liabilities
Provisions
Deferred tax 17 (1,027) (573) (87) (97)
Dilapidations on property leases (100)   (100)   (100)   (100)
TOTAL ASSETS LESS TOTAL LIABILITIES 98,173   85,359   75,653   70,137
 
EQUITY
Issued share capital 23 3,271 3,205 3,271 3,205
Share premium account 58,154 55,590 58,154 55,590
Treasury reserve - (1,144) - (1,144)
Revaluation reserve 664 654 395 385
Other reserves 26 2,449 2,028 2,449 2,028
Retained earnings 29,293   21,824   11,384   10,073
93,831 82,157 75,653 70,137
Non-controlling interests 24 4,342   3,202   -   -
TOTAL EQUITY 98,173   85,359   75,653   70,137
 

Approved by the Board and authorised for issue on 29 June 2017

STATEMENT OF CASHFLOWS

FOR THE YEAR ENDED 31 MARCH 2017

    Group   Group   Company   Company
2017 2016 2017 2016
Notes £000's £000's £000's £000's
Cashflows from operating activities
Profit before income tax 13,452 7,704 5,148 94
Adjustment for:
Net finance (income) 6 (784) (201) (927) (635)
Depreciation 12 & 13 264 242 15 20
Loss/(Profit) on disposal of non-current assets 37 (2) (8) -
Amortisation of intangible assets 11 3,088 2,681 - -
Impairment of intangible assets 297 - - -
Pension payments 21 (76) (55) (76) (55)
Share of associate's results 14 (23) (25) - -
Reversal of impairment of associate 14 - (30) - -
Share based payments 22 678   326   678   326
 

Operating cash flows before movements in working
capital

16,933 10,640 4,830 (250)
 
Change in inventories (4,082) (5,761) 925 (925)
Change in receivables (3,195) (2,432) (5,394) (5,122)
Change in payables 3,445   728   123   (616)
 
Cash generated from/(absorbed by) operations 13,101 3,175 484 (6,913)
Finance costs - (7) - (6)
Income tax (1,286)   (680)   (4)   (3)
Net cash from/(absorbed by) operating activities 11,815 2,488 480 (6,922)
 
Cash flows from investing activities
Acquisition of property, plant and equipment 12 (265) (364) (8) (6)
Disposal of property, plant and equipment - 6 8 -
Purchase of intangibles (net of
contributions from outside parties) 11 (7,931) (6,358) - -
Purchase of own shares - (43) - (43)
Finance income 6 103   67   927   642
Net cash (used in)/from investing activities (8,093) (6,692) 927 593
 
Cash flows from financing activities
Proceeds from issue of share capital
and sale of jointly owned and
treasury shares 3,834 5,513 3,834 5,513
Dividends paid (4,252)   (3,437)   (3,666)   (2,938)
Net cash (used in)/from financing activities (418)   2,076   168   2,575

Net increase/(decrease) in cash and cash
equivalents

3,304 (2,128) 1,575 (3,754)
Foreign exchange movements 1,633 58 - -
Balance at 1 April 2016 15,665   17,735   7,109   10,863
 
Balance at 31 March 2017 18 20,602   15,665   8,684   7,109
 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2017

1. General information

Eco Animal Health Group plc (“the company”) and its subsidiaries (together “the group”) manufacture and supply animal health products globally.

The Company is traded on the AIM market of the London Stock Exchange and is incorporated and domiciled in the UK. The address of its registered office is 78 Coombe Road, New Malden, Surrey, KT3 4QS.

2. Summary of significant accounting policies

2.1 Basis of preparation

The group has presented its annual report and accounts in accordance with International Financial Reporting Standards (IFRS), as adopted by the European Union, IFRIC interpretations and the Companies Act 2006 applicable to companies reporting under IFRS.

The preparation of financial statements, in conformity with IFRS as adopted by the European Union, requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on management’s best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

The principal accounting policies of the group are set out below and have been applied consistently in dealing with items which are considered material in relation to the Group’s financial statements.

2.2 Adoption of new and revised standards

The following amendments to existing standards and interpretations were effective for periods beginning after 1 January 2016, but the adoption of these amendments to existing standards and interpretations did not have a material impact on the financial statements of the Group:

The following new standards, amendments and interpretations to existing standards have been published that are mandatory for accounting periods beginning after 1 January 2016 (unless otherwise stated) and have not been applied in preparing these consolidated financial statements.

Beyond the information above, it is not practicable to provide a reasonable estimate of the effect of these standards until a detailed review has been completed.

The directors do not expect that the adoption of the Standards and Interpretations listed above will have a material impact on the financial statements of the Group in future periods.

2.3 Basis of consolidation

The consolidated financial statements comprise the accounts of the Company and its subsidiaries drawn up to 31 March 2017.

An entity is classed as a subsidiary of the Company when as a result of contractual arrangements the Company has the power to govern its financial and operating policies so as to obtain benefits from its activities.

The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group. The cost of an acquisition is measured, as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange. Identifiable assets acquired and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any minority interest. The excess of the cost of acquisition over the fair value of the Group’s share of the identifiable net assets acquired is recorded as goodwill. If the cost of acquisition is less than the fair value, the difference is recognised directly in the income statement.

Accounting policies have been changed where material to ensure consistency with the policies adopted by the Group. Although the subsidiaries in Brazil and China and the Joint operation in the USA and Canada all have December year ends, the Group uses management accounts to the end of March to prepare the Group accounts.

Subsidiaries are wholly consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation.

2.4 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting to the chief operating decision-maker. The chief operating decision-maker who is responsible for allocating resources and assessing performance of the operating segments has been identified as the Board.

2.5 Foreign currency translation

(a) Functional and presentational currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“functional currency”). The consolidated financial statements are presented in Pounds Sterling, which is the Company’s functional and the Group’s presentational currency.

(b) Transactions and balances

Monetary assets and liabilities denominated in foreign currencies are translated into Pounds Sterling at the rates of exchange ruling at the date of the financial statements.

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

Foreign exchange gains and losses that relate to borrowing and cash and cash equivalents are presented in the income statement within finance income or finance costs.

(c) Group companies

The results and financial position of all Group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows;

When a foreign operation is partially disposed or sold, exchange differences that were recognised in equity are recognised in the income statement as part of the gain or loss on sale. Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing exchange rate.

2.6 Financial instruments

a) Non-derivative financial assets

The Group initially recognises loans and receivables and deposits on the date that they are originated. All other financial assets (including assets designated at fair value through profit or loss) are recognised initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument.

The Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows from the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability.

Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends to settle on a net basis or to realise the asset and settle the liability simultaneously.

The Group has the following non-derivative financial assets:

b) Loans and receivables

Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognised initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition loans and receivables are measured at amortised cost using the effective interest method, less any impairment losses.

Loans and receivables comprise trade and other receivables and cash and cash equivalents.

Cash and cash equivalents comprise cash balances and call deposits with original maturities of three months or less. Bank overdrafts that are repayable on demand and form an integral part of the Group’s cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

c) Non-derivative financial liabilities

All financial liabilities (including liabilities designated at fair value through profit or loss) are recognised initially on the date at which the Group becomes a party to the contractual provisions of the instrument.

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled or expire.

The Group has the following non-derivative financial liabilities: bank overdrafts and trade and other payables.

Such financial liabilities are recognised initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortised cost using the effective interest method.

2.7 Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the costs of acquisition over the Group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition.

Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less any accumulated impairment losses. Goodwill is not subject to amortisation but is tested for impairment.

Negative goodwill arising on an acquisition is recognised directly in the income statement. On disposal of a subsidiary or a jointly controlled entity, the attributable amount of goodwill is included in the determination of the profit or loss recognised in the income statement on disposal. Goodwill arising before the date of transition to IFRS, on 1 April 2004, has been retained at the previous UK GAAP amounts, subject to being tested for impairment at that date. Goodwill written off to reserves under UK GAAP prior to 1998 has not been reinstated and is not included in determining any subsequent profit or loss on disposal.

2.8 Other intangible assets

Drug registrations, patents and licences

The Group recognises internally generated or externally acquired intangible assets at cost and subsequently recognises them at cost less accumulated amortisation and impairment losses. Intangible assets acquired as part of a business combination are recognised at fair value.

Expenditure on drug registrations and licences is recognised as an internally generated or externally acquired intangible asset only if all the following conditions are met:

All drug registrations and licences have previously been amortised on a straight-line basis over their useful economic life of 10 years. However, following the granting of Aivlosin’s first marketing authorisation in the USA in July 2012, which greatly increased the economic potential of the product, management revised their estimate of the useful life of the Aivlosin drug registrations only from 10 to 20 years and in accordance with IAS8 have amortised the remaining book value of the Aivlosin registrations over the remainder of the useful life of these registrations from that date.

Distribution rights

Distribution rights are recognised at cost and amortised on a straight line basis over their estimated useful economic life of 20 years. They are reviewed for impairment when any indication of potential impairment exists.

2.9 Property, plant and equipment and depreciation

Plant and equipment are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows;

Plant and machinery   20% on cost
Fixtures, fittings and equipment 20% on cost
Motor Vehicles 25% on cost

Freehold land and buildings are stated at valuation less depreciation. The property is professionally valued by a qualified surveyor at least once every three years. Surpluses and deficits arising from the periodic valuations are taken to the revaluation reserve in the statement of financial position and are recognised in the statement of comprehensive income for the year. Depreciation is provided at a rate calculated to write off the valuation less estimated residual value over the remaining useful life of the building at a rate of 2 per cent per annum. Land is not depreciated.

2.10 Impairment of non-financial assets

The carrying amounts of the Group’s assets are reviewed at each year end, to determine whether there is any indication of impairment. If any such indication exists, the asset’s recoverable amount is estimated in order to determine the impairment loss if any. The recoverable amount is the higher of its fair value and its value in use. For intangible assets with an indefinite useful life, an impairment test is performed at each year end.

In assessing value in use, the expected future cash flows from the asset are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is recognised in the income statement whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount.

A previously recognised impairment loss is reversed if the recoverable amount increases as a result of a change in the estimates used to determine the recoverable amount, but not to an amount higher than the carrying amount that would have been determined (net of depreciation) had no impairment loss been recognised in prior years.

2.11 Investment property

The investment property is property held either to earn rental income or for capital appreciation or for both, but not for sale in the ordinary course of business, use in the production or supply of goods or services or for administrative purposes. Investment property is measured at cost on initial recognition and subsequently at its valuation less any accumulated impairment and depreciation.

The property is professionally valued by a qualified surveyor at least once every three years. Surpluses and deficits arising from the periodic valuations are taken to the revaluation reserve in the statement of financial position and are recognised in the statement of comprehensive income for the year.

2.12 Investments

Non-current asset investments are stated at fair value, including transaction costs, less impairment. They are recognised or derecognised on the date when the contract for acquisition or disposal requires the delivery of that investment.

Investments in subsidiaries are stated at cost less impairment in the Parent Company’s statement of financial position.

An impairment is recognised in profit or loss when there is objective evidence that the asset is impaired and is measured on the difference between the investment’s carrying amount and the present value of estimated future cash flows discounted at the effective interest rate adjusted for a risk premium. Impairment losses are reversed in subsequent periods when an increase in the investment’s recoverable amount can be related objectively to an event occurring after the impairment was recognised, subject to the restriction that the carrying amount of the investment at the date the impairment is reversed shall not exceed what the amortised costs would have been had the impairment not been recognised.

Investments classified as available-for-sale are stated at fair value. Where securities are held for trading purposes, gains and losses arising from changes in fair value are included in net profit or loss for the period. For available-for-sale investments, gains and losses arising from changes in fair value are recognised directly in equity, until the security is disposed of or is determined to be impaired, at which time the cumulative gain or loss previously recognised in equity, determined using the weighted average cost method, is included in the net profit or loss for the period.

2.13 Interest in joint operations

A joint operation is a contractual arrangement whereby the Group and other parties undertake an economic activity that is subject to joint control; that is, when the strategic financial and operating policy decisions relating to the activities require the unanimous consent of the parties sharing control.

The group accounts for its interest in joint operations using proportional consolidation, as it has rights to substantially all of the economic benefits of the assets and obligations for the liabilities shown in these financial statements relating to those operations.

2.14 Investments in Associates

An associate is an entity in which an investor has significant influence but not control or joint control. Significant influence is defined as “the power to participate in the financial and operating policy decisions but not to control them.”

The group reports its interests in associates using the equity method of accounting. Under this method, an equity investment is initially recorded at cost (subject to initial fair value adjustment if acquired as part of the acquisition of a subsidiary), and is subsequently adjusted to reflect the group’s share of the net profit or loss of the associate. If the group’s share of losses of an associate equals or exceeds its “interest in the associate”, the group discontinues recognising its share of further losses. If the associate subsequently reports profits, the investor resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

2.15 Leasing

The Group leases certain property, plant and equipment.

Assets obtained under finance leases, where the Group has substantially all the risks and rewards of ownership are capitalised as property, plant and equipment and depreciated over the shorter of the lease term and their useful lives. Obligations under such agreements are included in borrowings net of the financial charge allocated to future periods. The financial element of the rental payment is charged to the income statement so as to produce constant periodic rates of charge on the net obligations outstanding in each period.

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the income statement on a straight-line basis over the period of the lease.

The Group reports its interests in jointly controlled entities using proportionate consolidation. The group’s share of the assets, liabilities, income, expenses and cash flows of jointly controlled entities are combined with the equivalent items in the results on a line-by-line basis.

2.16 Inventories

Inventories (including property under development) are valued at the lower of cost and net realisable value. Cost is determined using the first-in, first-out method. The cost of finished goods comprises raw materials, direct labour and other direct costs. Net realisable value is the estimated selling price in the ordinary course of business, less any costs which would be incurred in completing the goods and rendering them ready for sale.

2.17 Trade receivables

Trade receivables are initially measured at fair value and are subsequently measured at amortised cost using the effective interest rate method. Appropriate allowance for estimated, irrecoverable amounts are recognised in profit or loss when there is objective evidence that the asset is impaired. The allowance recognised is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows discounted at the effective interest rate computed at initial recognition.

2.18 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held on call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the statement of financial position.

2.19 Financial liabilities and equity

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities.

2.20 Bank borrowings and loans

Interest-bearing bank loans and overdrafts are recorded as the proceeds received, net of direct issue costs (which equate to fair value). Finance charges including premiums payable on settlement or redemption and direct issue costs are accounted for on an accruals basis in profit or loss using the effective interest rate method and are added to the carrying amount of the instrument to the extent that they are not settled in the period in which they arise.

2.21 Trade payables

Trade payables are initially measured at fair value and are subsequently measured at amortised cost using the effective interest rate method.

2.22 Provisions

Provisions are recognised when the Group has a present obligation as a result of a past event and it is probable that the Group will be required to settle the obligation. Provisions are measured at the directors’ best estimate of the expenditure required to settle the obligation outstanding at the year end and are discounted to present value where the effect is material.

2.23 Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods in the ordinary course of the Group’s activities. Revenue is shown net of value added tax, returns, rebates and discounts and after eliminating sales within the Group.

The Group recognises revenue on despatch of the goods (which the directors believe transfers substantially all the risks and rewards of ownership to the buyer). No goods are despatched on a sale or return basis. Distributors trade on their own account and not as agents.

The Group also receives interest, rental income, royalty income and management charges in respect of accounting services supplied to certain ex-subsidiaries. The amounts are small and are recognised on an accruals basis.

2.24 Pensions

Defined Contribution Scheme

The pension costs charged against operating profits represent the amount of the contributions payable to the schemes in respect of the accounting period.

Defined Benefit Scheme

The regular cost of providing retirement pensions and related benefits is charged to the income statement over the employees’ service lives on the basis of a constant percentage of earnings. The present value of the defined benefit obligation less the fair value of the plan assets is disclosed as an asset or liability in the statement of financial position in accordance with IAS19. The disclosure of a net defined benefit asset is limited to the present value of any economic benefit available in the form of refunds from the plan or reductions in future contributions to the plan.

Actuarial gains or losses are taken directly to equity in the statement of comprehensive income.

2.25 Share-based payments

The Group has applied the requirements of IFRS2 Share-based payments. In accordance with the transitional provisions, IFRS2 has been applied to all grants of equity instruments after 7 November 2002 that were unvested at 1 January 2005.

The Group issues equity-settled share-based payments to certain employees in exchange for services from those employees. Equity-settled share-based payments are measured at fair value (excluding the effect of non-market based vesting conditions) at the date of grant. The fair value determined at the grant of such equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of shares that will eventually vest and adjusted for the effect of non-market based vesting conditions (with a corresponding movement in equity).

The Group’s Employee Benefit Trust (“the Trust”) was set up on 6 October 2011 to administer the Group’s Joint Share Ownership Plan (JSOP). The trust is funded by loans from the Group, with its assets comprising shares in the Company. The Group recognises the assets and liabilities of the Trust in its own accounts and the carrying value of the Company’s shares held by the Trust are recorded as a deduction in total equity until such a time as the shares vest unconditionally to employees.

Fair value, for both options and jointly owned shares is measured by use of the Black-Scholes model. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behaviour considerations.

Further details of the inputs to the Black-Scholes model can be found in note 22 to the accounts.

2.26 Taxation

Tax expense for the period comprises current and deferred tax.

Current tax, including UK corporation tax and foreign tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantially enacted by the year end. Tax expenses are recognised in the income statement or statement of comprehensive income according to the treatment of the transactions which give rise to them.

Deferred income tax is recognised, using the liability method, on temporary differences arising between the tax basis of assets and liabilities and their carrying amount in the financial statements.

Deferred income tax is determined using tax rates (and laws) that have been enacted, or substantially enacted, by the date of the statement of financial position and are expected to apply when the related deferred tax asset is realised or deferred tax liability is settled.

Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised.

2.27 Equity

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Amounts arising on the restructuring of equity and reserves to protect creditor interests are credited to the capital redemption reserve.

The cost of its own shares bought into treasury by the company is debited to retained earnings as required by the Companies Act 2006. A subsequent sale of these shares would result in this entry being wholly or partly reversed with any profit on the sale being credited to Share Premium.

The Treasury reserve arises when the Company issues equity share capital under its Joint Share Ownership Plan, which is held in trust by ECO Animal Health Group plc Employee Benefit Trust. The interests of this trust are consolidated into the Group’s financial statements and the relevant amount treated as a reduction in equity. The expenses of the trust are included in the consolidated income statement.

2.28 Non-controlling (minority) interest

For each business combination, the Group elects to measure any non-controlling interest in the acquiree either at fair value or at their proportionate share of the acquiree’s identifiable net assets which are generally at fair value. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as transactions with owners in their capacity as owner. Adjustments to non-controlling interests are based on a proportionate amount of the net assets of the subsidiary. No adjustments are made to goodwill and no gain or loss is recognised in the statement of profit or loss.

2.29 Dividend distribution

Final dividend distributions to the Company’s shareholders are recognised as liabilities in the financial statements in the period in which they are approved by the Company’s shareholders. Interim dividends are recognised when they are paid.

2.30 Critical accounting estimates and judgements

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are:

(a) Estimated impairment value of intangible assets

The Group tests annually whether intangible assets with indefinite life have suffered any impairment. Other intangible assets are reviewed for impairment when an indication of potential impairment exists. Impairment provisions are recorded as applicable based on directors’ estimates of recoverable values. Details of the impairment reviews performed can be found in note 11 of the financial statements.

(b) Income taxes

The Group is subject to income taxes predominantly in the United Kingdom but also in other jurisdictions.

Significant estimates are required in determining the provision for income taxes. There are some transactions and calculations for which the ultimate tax determination is uncertain. The Group recognises assets and liabilities based on estimates of the final agreed position.

Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

(c) Pension scheme

The Group maintains one defined benefit pension scheme which has been accounted for according to the provisions of IAS19. Although the assumptions were determined by a qualified actuary, any change in those assumptions may materially impact the financial position and results of the Group. Details of the assumptions used can be found in note 21 of the financial statements.

(d) Share-based payments

The charge to the Income Statement in respect of share-based payments has been externally calculated using management’s best estimates of the amount of options expected to vest and various other inputs to the Black-Scholes model, as disclosed in note 22. Any variation in those assumptions may have a material impact on the Group’s future results and financial position.

3. Segment information

Management has determined the operating segments based on the reports reviewed by the Board that are used to make strategic decisions. The Board considers the business from a geographical perspective. Geographically, management considers the performance in the UK and Europe, the Far East, Latin America, North America and the Middle East and Africa.

Management considers Earnings before Interest, Tax, Depreciation and Amortisation (“EBITDA”), adjusted for share-based payments.

             
Corporate/U.K. Europe Far East Latin America North America Middle East and Africa Total
£000's £000's £000's £000's £000's £000's £000's
 
Year ended 31 March 2017
Total segmental revenue 1,265 7,986 43,041 10,554 21,521 1,621 85,988
Inter-segment revenue -   -   (8,982)   (3,109)   (12,475)   -   (24,566)
 
Revenue from external customers 1,265   7,986   34,059   7,445   9,046   1,621   61,422
 
Sale of goods 1,265 7,986 34,059 7,445 9,046 1,399 61,200
Royalties -   -   -   -   -   222   222
1,265   7,986   34,059   7,445   9,046   1,621   61,422
 
Adjusted EBITDA (1,420) 2,025 11,142 1,512 3,151 599 17,009
Total assets 27,612   13,954   39,452   15,907   12,987   3,845   113,757
 
 
Year ended 31 March 2016
Total segmental revenue 1,202 6,943 29,024 11,372 16,287 1,693 66,521
Inter-segment revenue -   -   (6,128)   (4,067)   (9,188)   -   (19,383)
 
Revenue from external customers 1,202   6,943   22,896   7,305   7,099   1,693   47,138
 
Sale of goods 1,202 6,943 22,896 7,305 7,099 1,535 46,980
Royalties -   -   -   -   -   158   158
1,202   6,943   22,896   7,305   7,099   1,693   47,138
 
Adjusted EBITDA (1,269) 1,388 6,913 1019 2,275 369 10,695
Total assets 20,429   12,589   32,451   15,882   11,059   4,553   96,963
 

Goodwill and other intangible assets are initially allocated to the geographical segments on the basis of the proportion of sales achieved by each segment.

A reconciliation of adjusted EBITDA to profit before tax is provided as follows:

      2017       2016    
£000's £000's
 
Adjusted EBITDA for reportable segments 17,009 10,695
Depreciation (264) (242)
(Losses)/Profits on disposal of fixed assets (37) 2
Amortisation (3,088) (2,681)
Impairment of intangible assets (297) -
Share-based payment charges (678) (326)
Finance income 784 201
Share of associate's results 23 25
Reversal of impairment re associate -       30
Profit before tax on continuing activities 13,452       7,704
 

4. Other income

      2017       2016    
£000's £000's
 
Management charges 166 155
Rental income 145 177
Sundry income 68       5
379       337
 

Sundry income in the year relates to the gain on the sale of the property acquired for development in the previous year. The group used some of its surplus cash reserves to fund the £1.33m cost of the project and received £1.4m on the sale of the property. This represents a much larger return to shareholders than was available from bank deposits over the same period.

5. Result from operating activities

  2017   2016
£000's £000's
 
Result from operating activities is stated after charging/(crediting)
Cost of inventories recognised as an expense 30,990 25,994
Employee benefits expenses 8,103 6,034
Amortisation of intangible assets 3,088 2,681
Impairment of intangible assets 297 -
Depreciation (notes 12 &13) 264 242
Loss/(profit) on disposal of assets 37 (2)
Loss on foreign exchange transactions 55 361
Research and development 36 20
Operating lease rentals 638 480
 
Fees payable to the Company's auditor for the audit of the parent Company and Group annual accounts 17 17
For the audit of the Company's subsidiaries 41 36
Fees payable for audit of the Company's subsidiaries pursuant to legislation 9   8
 
2017 2016
£000's £000's
 
Earnings due to shareholders before interest, tax, depreciation, amortisation, share-based
payments and foreign exchange differences
 
Profit from operating activities 12,645 7,448
Depreciation 264 242
Loss/(Profit) on disposal of fixed assets 37 (2)
Amortisation 3,088 2,681
Impairment of intangible assets 297 -
Share-based payments 678   326
 
17,009 10,695
Foreign exchange differences 55   361
17,064   11,056
 

6. Finance income

  2017   2016
£000's £000's
Finance income
Interest received on short term bank deposits 103 67
Foreign exchange differences on bank balances 681   141
784   208
Finance costs
Interest paid -   (7)
-   (7)
 
784   201
 

7. Earnings per share

The calculation of basic earnings per share is based on the post-tax profit for the year divided by the weighted average number of shares in issue during the year.

  2017       2016    
Earnings Weighted Per share Earnings Weighted Per share
average amount average amount
number of number of
shares shares
£000's 000 (pence) £000's 000 (pence)
Earnings attributable to
ordinary shareholders on
continuing operations
after tax 10,565 64,638 16.35 6,037 62,170 9.71
Dilutive effect of share options - 718 (0.18) - 988 (0.15)
                     
Fully diluted earnings per share 10,565   65,356   16.17   6,037   63,158   9.56
 

Diluted earnings per share takes into account the dilutive effect of share options. For the purposes of calculating earnings per share, shares held by the Employee Benefit Trust as part of the Joint Share Ownership Plan are excluded from the calculation of the weighted average number of shares. The weighted average number of shares held by the Trust during the year was 138,246 (2016: 1,521,594).

8. Taxation

  2017   2016
£000's £000's
Current tax year
Foreign corporation tax on profits for the year 1,183 693
Withholding tax on intercompany dividend 61 42
Research and development tax credits claimed (255) (98)
 
Deferred tax
Origination and reversal of temporary differences 469 403
Due to change in effective rate (5)   (45)
Income tax charge 1,453   995
 
2017 2016
£000's £000's
Factors affecting the tax charge for the year
Profit on ordinary activities before taxation 13,452   7,704
 
Profit on ordinary activities before taxation multiplied by the
applicable rate of UK corporation tax of 20% 2,690 1,541
Effects of:
Non deductible expenses 557 358
Non chargable credits (742) (291)
Withholding tax on inter-company dividends 61 42
Enhanced allowance on research and development expenditure (1,078) (764)
Different tax rate for foreign subsidiaries 214 111
Reduced effective deferred tax rate (5) (45)
Unused tax losses carried forward 2 43
Patent box claim (275) -
Other adjustments 29   -
Income tax charge 1,453   995
 
2017 2016
% %
Applicable tax rate per UK legislation 20.00 20.00
Effects of:
Non deductible expenses 4.14 4.65
Non chargable credits (5.51) (3.77)
Withholding tax on inter-company dividends 0.45 0.54
Enhanced allowance on research and development expenditure (8.02) (9.92)
Different tax rate for foreign subsidiaries 1.59 1.44
Reduced effective deferred tax rate (0.04) (0.58)
Unused tax losses caried forward 0.02 0.56
Patent box claim (2.05) -
Other adjustments 0.22   -
Effective tax rate 10.80   12.92
 

Deferred tax balances at the year end have been measured at 18%, which was expected to be the rate in force when they become payable.

9. Profit for the financial year

  2017   2016
£000's £000's
 
Parent Company's profit for the financial year 5,144   91
 

The Company has elected to take the exemption under Section 408 of the Companies Act 2006 not to present the Parent Company income statement.

10. Dividends

  2017   2016
£000's £000's
 
Dividend for the period ended 31 March 2015 of 4.75p per ordinary share - 3,020
Dividend for the period ended 31 March 2016 of 5.7p per ordinary share 3,675 -
Dividend waived by Employee Benefit Trust (8) (80)
     
3,667   2,940
 

The Board is declaring a dividend of 7.1 pence per share in respect of the year ended 31 March 2017.

11. Intangible fixed assets

Group   Goodwill   Distribution   Drug   Total
rights registrations,
patents and
license costs
£000's £000's £000's £000's
Cost
At 1 April 2015 17,930 1,442 53,356 72,728
Additions - internally generated - - 5,885 5,885
Additions- acquired separately - - 473 473
Foreign exchange movements -   -   (2)   (2)
At 1 April 2016 17,930 1,442 59,712 79,084
Additions - internally generated - - 8,238 8,238
Contributions from outside parties -   -   (307)   (307)
At 31 March 2017 17,930   1,442   67,643   87,015
 
Amortisation
At 1 April 2015 - 615 26,453 27,068
Charge for the year - 72 2,609 2,681
Foreign exchange movements -   -   (2)   (2)
At 1 April 2016 - 687 29,060 29,747
Charge for the year - 72 3,016 3,088
Impairment for the year -   -   297   297
At 31 March 2017 -   759   32,373   33,132
 
Net Book Value
At 31 March 2017 17,930   683   35,270   53,883
 
At 31 March 2016 17,930   755   30,652   49,337
 
At 31 March 2015 17,930   827   26,903   45,660
 

The amortisation and impairment charges are included within administrative expenses on the income statement.

Distribution rights are amortised over their estimated useful life of 20 years and reviewed for impairment when any indication of potential impairment exists. The remaining amortisation period at the date of the financial statements ranged from 6 to 17 years.

The carrying value of goodwill is attributable to the following cash generating units:

Entity   Date of acquisition  

£000’s

Eco Animal Health Limited 1 October 2004 17,359
Zhejiang Eco Biok Animal Health Products Limited 1 April 2007 94
ECO Animal Health Japan Inc 24 December 2009 477
 
17,930
 

Goodwill acquired in a business combination is allocated at acquisition to the cash generating units (CGU’s) that are expected to benefit from the business combination.

The recoverable amounts of the CGU’s are determined from value in use calculations. The key assumptions for the value in use calculations are those regarding discount rates, growth rates and the estimated remaining useful life of the asset which is maintained at 30 years through ongoing investment in the cash generating unit.

The Group prepares cash flow forecasts derived from the most recent financial budgets and projections that are approved by management for the year ahead and then extrapolates them assuming a 3% annual growth rate which is well below the current performance of the existing business. The directors believe that the long term growth rate assumed does not exceed the average long term growth rate for the relevant markets.

Management estimates discount rates using the pre-tax rates that reflect current market assessments of the time value of money and the risks specific to the CGU’s. In the current year management estimated the applicable rate to be 11%. Management considers that there is adequate headroom when comparing the net present value of the cash flows to the carrying value of goodwill to conclude that no impairment is necessary this year. On current assumptions the excess of recoverable amount over carrying value is over £78 million (2016: £67 million).

Management believes that the most significant assumption in the calculation of value in use is the estimated growth rate. However, even if the growth rate were to be zero, the recoverable amount would still be over £51 million more than the carrying value and no impairment would be necessary.

The net book value of Drug registrations and licenses can be broken down as follows:

    £000's    
Aivlosin 33,723
Ecomectin 1,473
Otehrs 74
35,270

Aivlosin is a highly effective antibiotic that treats a range of specific enteric (gut) and respiratory diseases in pigs and poultry, ensuring a rapid return to health. In addition to the welfare benefits, healthy animals gain weight faster, digest food more efficiently and get to market earlier which all bring economic benefit to the farmer. Substantial ongoing product development covering more formulations, species and diseases is expected to substantially further increase its revenue generating potential. The remaining amortisation period is from 6 to 20 years.

Ecomectin is an endectocide that controls worms, ticks, lice and mange in grazing stock and pigs. The remaining amortisation period is 0 to 10 years.

Drug registrations and licences are amortised over their estimated useful lives of 10 to 20 years, which is the directors’ estimate of the time it would take to develop a new product allowing for the Group’s patent protection and the exclusivity period which comes with certain registrations. Given the economic climate the directors have conducted an impairment review in the current year by preparing cash flow projections for the year ahead and extrapolating the results for the remaining life of the registrations assuming zero growth and an 11% discount rate to establish value in use. On the current assumptions the excess of the value in use over carrying value is over £6 million (2016: £12 million).

Fair value calculated as 10 times the current cash generated by the registrations gives an even higher value of £127m and this higher figure determines the recoverable amount, so management has again concluded that no impairment is necessary.

A review of individual projects has identified that an impairment in the year of £297,000 (2016: £nil) would be appropriate.

12. Property, plant and equipment

Group   Land and   Plant and   Fixtures,   Motor   Total
Buildings machinery fittings Vehicles
(freehold) and
equipment
£000's £000's £000's £000's £000's
Cost or valuation
At 1 April 2015 650 1,427 631 86 2,794
Revaluation in the year 80 - - - 80
Additions - 285 79 - 364
Foreign exchange movements - (23) - - (23)
Disposals -   (31)   -   (33)   (64)
At 1 April 2016 730 1,658 710 53 3,151
Additions - 47 155 63 265
Foreign exchange movements - 116 - 6 122
Disposals     (280)   -   (47)   (327)
At 31 March 2017 730   1,541   865   75   3,211
 
Depreciation
At 1 April 2015 18 653 442 62 1,175
Charge for the year 10 157 62 9 238
Revaluation adjustment (28) - - - (28)
Foreign exchange movements - (9) 3 - (6)
Disposals -   (29)   -   (32)   (61)
At 1 April 2016 - 772 507 39 1,318
Charge for the year 13 166 78 7 264
Foreign exchange movements - 51 2 - 53
Disposals -   (252)   -   (37)   (289)
At 31 March 2017 13   737   587   9   1,346
 
 
Net Book Value
At 31 March 2017 717   804   278   66   1,865
 
At 31 March 2016 730   886   203   14   1,833
 
At 1 April 2015 632   774   189   24   1,619
 

The freehold property at 78 Coombe Road, New Malden was valued on 11 May 2016 by Mr R Sworn of Kelion Sworn Chartered Surveyors and Valuers, London, W1. The fair value in use of the freehold property was determined at £730,000 by means of applying a 7.5% discount rate to the annual rental value of the property as determined by local market conditions. The property will continue to be valued on a regular basis.

The value of non-depreciable land included within Land and Buildings is £180,000.

The freehold property of 78 Coombe Road, New Malden is subject to a legal charge held by the company’s bankers dated 20 March 1987.

The value of the freehold property would have been recorded at £280,000 (2016: £284,000) on a historical cost basis giving rise to the current revaluation surplus of £360,000 net of deferred tax provision. This balance is not distributable to shareholders.

Depreciation has been included in the administrative expenses line on the income statement, except £114,000 (2016: £115,000) of depreciation of production equipment in the Chinese subsidiary ECO Biok, which is included within cost of sales.

Company   Land and   Fixtures,   Motor   Total
Buildings fittings Vehicles
(freehold) and
equipment
Cost or valuation £000's £000's £000's £000's
 
At 1 April 2015 650 149 26 825
Additions - 6 - 6
Revaluation in the year 80   -   -   80
At 1 April 2016 730 155 26 911
Additions - 8 - 8
Disposals -   -   (26)   (26)
At 31 March 2017 730   163   -   893
 
Depreciation
At 1 April 2015 18 145 22 185
Charge for the year 10 2 4 16
Revaluation adjustment (28)   -   -   (28)
 
At 1 April 2016 - 147 26 173
Charge for the year 12 3 - 15
Revaluation adjustment -   -   (26)   (26)
At 31 March 2017 12   150   -   162
 
 
Net Book Value
At 31 March 2017 718   13   -   731
 
At 31 March 2016 730   8   -   738
 
At 1 April 2015 632   4   4   640
 

13. Investment property

Group and Company    
Land and Total
Buildings
(freehold)
£000's £000's
Cost /Revaluation      
At March 2015, March 2016 and March 2017 189   189
 
Depreciation
At March 2015, - -
Charge for the year ended March 2016 4   4
At March 2016 and March 2017 4   4
 
Net Book Value
At 31 March 2017 185   185
 
At 31 March 2016 185   185
 
At 1 April 2015 189   189
 

The property in Western Road, Mitcham was valued at £189,000 as at 31 March 2015 by Mr R. Sworn of Kelion Sworn Chartered Surveyors, London W1. This property was previously the Head Office of Lawrence plc (now ECO Animal Health Group plc) and is occupied by a charity.

The value of the investment property would have been recorded at £139,000 on a historical cost basis giving rise to the current revaluation surplus of £36,000 net of deferred tax provision. This balance is not distributable to shareholders.

14. Fixed asset investment

Group      
Investment in Unlisted Total
Associate investments
(Equity) (Cost)
£000's £000's £000's
At March 2015 - 9 9
Reversal of previous impairments 30 - 30
Share of associate's result for the year 25   -   25
At March 2016 55 9 64
Share of associate's result for the year 23 - 23
Foreign exchange differences 10   -   10
At March 2017 88   9   97
 
Company
Unlisted Total
investments
(subsidiaries)
Cost or fair value £000's £000's
At March 2015, 2016 and 2017 21,273   21,273
 
Impairment
At March 2015, 2016 and 2017 1,191   1,191
 
Net Book Value
At March 2015, 2016 and 2017 20,082   20,082
 

The Company holds more than 20% of the share capital of the following companies:

Company  

Country of
registration or
incorporation

  Class   Shares held %
 
Subsidiary undertakings held by Company
Zhejiang ECO Biok Animal Health Products Limited P. R. China Ordinary 3
Shanghai ECO Biok Veterinary Drug Sale Company Ltd. (via Zhejiang ECO Biok Animal Products Ltd.) P. R. China Ordinary 3
Petlove Limited Great Britain Ordinary 91
Eco Animal Health Limited Great Britain Ordinary 100
 
Subsidiary undertakings held by Group
ECO Animal Health Southern Africa (Pty) Limited South Africa Ordinary 100
Zhejiang ECO Biok Animal Health Products Limited P. R. China Ordinary 48
Shanghai ECO Biok Veterinary Drug Sale Company Ltd. (via Zhejiang ECO Biok Animal Products Ltd.) P. R. China Ordinary 48
ECO Animal Health do Brasil Comercio de Produtos Veterinarios Ltda. Brazil Ordinary 100
ECO Animal Health Japan Inc Japan Ordinary 100
ECO Animal Health USA Corp. U.S.A. Ordinary 100
Interpet LLC U.S.A. Ordinary 100
ECO Animal Health de Mexico, S. de R. L. de C. V. Mexico Ordinary 100
ECO Animal Health de Argentina S.A. Argentina Ordinary 100
ECO Animal Health Malaysia Sdn. Bhd Malaysia Ordinary 100
ECO Animal Health India Private Ltd India Ordinary 100
 

The principal activity of these undertakings for the last relevant financial year was as follows:

  Principal activity
ECO Animal Health Limited Distribution of animal drugs
ECO Animal Health Southern Africa (Pty) Limited Non-trading
Petlove Limited Non-trading
Zhejiang ECO Biok Animal Health Products Limited Manufacture of animal drugs
Shanghai ECO Biok Veterinary Drug Sale Company Ltd. Distribution of animal drugs
ECO Animal Health do Brasil Comercio de Produtos Veterinarios Ltda Distribution of animal drugs
ECO Animal Health Japan Inc. Distribution of animal drugs
ECO Animal Health USA Corp. Distribution of animal drugs
Interpet LLC Non-trading
ECO Animal Health de Mexico, S. de R. L. de C. V. Distribution of animal drugs
ECO Animal Health de Argentina S.A. Non-trading
ECO Animal Health Malaysia Sdn. Bhd Non-trading
ECO Animal Health India Private Ltd Non-trading
 

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were:

  Equity   Profit/(loss)   Equity   Profit/(loss)
for the year for the year
2017 2017 2016 2016
£000's £000's £000's £000's
 
ECO Animal Health Limited 18,871 10,809 13,062 6,692
ECO Animal Health Southern Africa (Pty) Limited 234 18 217 (121)
Zhejiang ECO Biok Animal Health Products Ltd 8,857 2,926 6,531 551
ECO Animal Health do Brasil Comercio de Produtos Veterinarios Ltda. 1,102 (261) 1,060 9
ECO Animal Health Japan Inc. 1,106 90 867 73
ECO Animal Health de Mexico, S. de R. L. de C. V. (317) (8) (290) (97)
ECO Animal Health USA Corp. 27 42 (11) 105
 

The equity and results of Shanghai ECO Biok Veterinary Drug Sale Company Ltd are included within those disclosed for Zhejiang ECO Biok Animal Health Products Limited.

All of the subsidiaries listed above were included in the consolidation for the year.

Zhejiang ECO Biok Animal Health Products Limited and ECO Animal Health do Brasil Comercio de Produtos Veterinarios Ltda both have 31 December year ends. The Group receives management accounts for the three months to 31 March for these subsidiaries for use in preparing the consolidated financial statements.

ECO Argentina S.A. which holds neither assets nor liabilities and which has not traded since formation have been excluded from consolidation. Interpet LLC has also been excluded from consolidation as it holds no assets or liabilities and has ceased trading.

The following trading subsidiaries have no requirement for audit under local legislation;

ECO Animal Health do Brasil Comercio de Produtos Veterinarios Ltda.

ECO Animal Health Japan Inc.

ECO Animal Health USA Corp.

ECO Animal Health de Mexico, S. de R. L. de C. V.

Joint Operations

The Group also holds (by means of its ownership of ECO Animal Health USA Corp.), a 50% interest in Pharmgate Animal Health LLC, which is resident in the U.S.A. Pharmgate Animal Health LLC distributes the group’s products in the U.S.A.

The Group also holds a 50% interest in Pharmgate Animal Health Canada Inc, which distributes its products into Canada.

Both Pharmgate Animal Health LLC and Pharmgate Animal Health Canada Inc. have accounting years which end on 31 December.

The group’s holdings in each of the joint operations’ share capital is given in the table below:

Pharmgate Animal Health Canada Inc

  Holding   Shares   Holding
(shares) in issue %
 
Common Shares 100 200 50
Class A shares 100 100 100
Class B Shares - 100 -
 
Pharmgate Animal Health USA LLC Holding Shares Holding
(shares) in issue %
 
Common Shares 100 200 50
Class A shares 100 100 100
Class B Shares - 100 -
 

In each case class A shares carry the rights to dividends payable out of profits attributable to the group. These are made up of profits made by products supplied by the ECO group plus 50% of any profit relating to new products developed jointly by the partners to the joint operation.

The following amounts included in the group’s financial statements are related to its interest in these joint operations.

      Pharmgate Animal Health
Pharmgate LLC Canada Inc
2017 2016 2017   2016
£000's £000's £000's £000's
Current assets 935 1,483 461 494
Current liabilities (907) (1,461) (461) (493)
Sales 6,145 4,224 2,462 2,681
Expenses (1,285) (892) (274) (247)
 

Associated Company

The Group also holds (by means of its ownership of ECO Animal Health Japan Inc.) a 47.62% interest in EcoPharma.com which is resident in Japan. This company distributes Animal Health products and other general merchandise within Japan.

ECO Animal Health Japan Inc’s holding in EcoPharma.com is 10,000,000 shares out of a total of 21,000,000 shares.

The following amounts included in the group’s financial statements are related to its interests in this associated company.

  2017   2016
£000's £000's
 
Investments (share of net assets)
 
At 1 April 2016 55 -
Share of results for the year 23 25
Reversal of previous impairment - 30
Foreign exchange movement 10   -
At 31 March 2017 88   55
 

15. Inventories

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Raw materials and consumables 14,503 9,824 - -
Finished goods and goods for resale 4,493 4,373 - -
Work in progress 679 472 - -
Property under development -   925   -   925
19,675   15,594   -   925
 

The cost of inventories recognised as an expense and included in cost of sales in the period amounted to £30,894,000 (2016: £25,994,000).

16. Trade and other receivables

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Trade receivables 14,912 12,036 - -
Amounts owed by group undertakings - - 46,043 41,002
Amounts owed by joint operations 390 490 - -
Other receivables 286 610 22 348
Prepayments and accrued income 570   493   67   59
16,158   13,629   46,132   41,409
 

As at 31 March 2017, trade receivables of £1,936,000 (2016: £2,373,000) due to the Group and £nil (2016: £nil) due to the Company were past due but not impaired. These relate to long standing distributors with whom we have agreed settlement terms and with whom there is no history of default. The ageing analysis of these trade receivables is as follows:

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Up to 3 months past due 1,548 1,621 - -
3 to 6 months past due 382 709 - -
Over 6 months past due 6   43   -   -

 

1,936   2,373   -   -
 

As at 31 March 2017, trade receivables of £501,000 (2016: £453,000) were impaired and provided for. The impaired receivables mainly relate to historic debt for which recovery is still being sought. The Group mitigates its exposure to credit risk by extensive use of commercial credit reference agencies, close management of its customers’ trading against terms offered and use of retention of title clauses wherever possible. The ageing analysis of the impaired balances is as follows:

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
Current debt 9 - - -
Up to 3 months past due 31 109 - -
3 to 6 months past due 131 167 - -
Over 6 months past due 330   177   -   -
501   453   -   -
 

Movement on the Group provision for impairment of trade receivables is as follows:

   
Group 2017 2016
£000's £000's
 
 
Balance at 1 April 453 276
Provided in the year (net of recoveries) 48 194
Written off in the year -   (17)
Balance at 31 March 501   453
 

The carrying amounts of trade and other receivables are denominated in the following currencies:

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
 
Pounds Sterling 574 987 46,132 41,409
Euros 3,883 3,062 - -
U S Dollars 7,184 5,442 - -
Chinese RMB 1,624 1,195 - -
Brazilian Real 846 748 - -
Japanese Yen 644 563 - -
Canadian dollars 441 839 -
Other currencies 962   793   -   -
 
16,158 13,629 46,132 41,409
 

The carrying amounts of trade and other receivables are not significantly different to their fair values.

17. Deferred tax

Group

Deferred tax assets and liabilities are attributable to the following:

  Liabilities     Net  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Drug registration expenditure (2,785) (2,337) (2,785) (2,337)
Freehold property (79) (89) (79) (89)
Investment property (8) (8) (8) (8)
Plant and equipment (43) (27) (43) (27)
Tax losses carried forward 1,888   1,888   1,888   1,888
Amount (payable) after more than one year (1,027)   (573)   (1,027)   (573)
 

The movement on the deferred tax account can be summarised as follows:

  Drug   Freehold   Investment   Total
registration property property
expenditure
 
£000's £000's £000's £000's
 
At 1 April 2016 (476) (89) (8) (573)
(Charge) for the year through income statement (464) - - (464)
Credit for the year through revaluation reserve -   10   -   10
At 31 March 2017 (940)   (79)   (8)   (1,027)
 

The tax losses carried forward are not expected to expire under current legislation.

Any future dividend received from the Chinese subsidiary Zhejiang ECO Biok Animal Health Products Limited will be subject to a 10% withholding tax (reduced to 5% in respect of dividends paid out of profits made in 2015 or after). The deferred tax liability in respect of this has not been recognised.

Company   2017   2017   2017   2016   2016   2016
Freehold Investment Total Freehold Investment Total
property property property property
£000's £000's £000's £000's £000's £000's
 
At 1 April (89) (8) (97) (66) (9) (75)
Movement in the year through revaluation reserve 10   -   10   (23)   1   (22)
At 31 March (79)   (8)   (87)   (89)   (8)   (97)
 

No charge or credit (2016: no charge or credit) was recognised in the Company’s income statement for the year. A credit of £10,000 (2016: charge of £22,000) was recognised in the Company’s Revaluation Reserve.

18. Cash and cash equivalents

Cash and cash equivalents comprise cash and short term deposits held by the Group. The carrying amount of these assets are not significantly different to their fair value.

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Cash and cash equivalents 20,602   15,665   8,684   7,109
Net funds per cash flow 20,602   15,665   8,684   7,109
 

19. Trade and other payables

  Group     Company  
2017 2016 2017 2016
£000's £000's £000's £000's
 
Trade payables 11,132 8,281 115 83
Amounts due to joint operation - 87 - -
Other payables 1,790 961 403 85
Accruals and deferred income 811   1,044   8   61
13,733   10,373   526   229
 

20. Borrowings

The Group has the facility to overdraw in specific currencies but no net facility. The interest rate for all currency overdrafts is 2.75 per cent over the relevant currency base rate and the borrowings are secured by two debentures held over all assets of the company dated 28 January 1995 and 28 November 2006.

21. Pension and other post-retirement benefit commitments

Defined Contribution Pension Scheme

The Group operates defined contribution pension schemes for the benefit of certain directors and senior employees. The assets of the schemes are held separately from the Group and independently administered by insurance companies. The pension cost charge represents contributions payable to the funds in the year and amounted to £269,000 (2016: £452,000).

Defined Benefit Pension Scheme

The Group operates a defined benefit scheme in the UK for ex-employees only. A full actuarial valuation was carried out at 6 April 2012 and updated 31 March 2017 by a qualified independent actuary. The major assumptions used by the actuary were:

  31 March   1 April
2017 2016
Discount rate 2.8% 3.50%
Rate of increase in pension payment 2.25% 1.95%
Inflation assumption with a maximum of 5% p.a. 3.25% 2.95%
 

Mortality rates

Pre-retirement mortality is based on the mortality table known as AMCOO for males and AFCOO for females and 70% of the mortality indicated by this table has been taken, as in the previous year.

Post retirement mortality is based on the mortality table known as S2NMA for males and S2NFA for females with reference to member’s years of birth. Allowance has been made for the improvement in mortality experienced recently and expected in the future by using 100% of the CMI’s 2016 improvement table, subject to a minimum improvement rate of 1.25% (2016: 1.25%) for males and 1% (2016: 1%) for females. The previous figures used S1NMA/S1NFA, CMI 2015 and the same long term rates.

Defined Contribution Pension Scheme

Under these mortality assumptions, the expected future lifetime for a member retiring at age 65 at the year end would be 22.6 years for males (2016: 22.4 years) and 24.3 years for females (2016: 24.4 years). For members retiring in 20 years time, the expectation of life would be 23.9 years for males (2016: 24 years) and 25.5 years for females (2016: 25.9 years).

The weighted average term of the liabilities is 23 years (2016: 16 years).

The scheme is exposed to a number of risks including:

1. Interest rate risk: Movements in the discount rate used could affect the present value of the defined benefit pension obligations.

2. Longevity risk: Changes in the estimated mortality rates of former employees could affect the present value of the defined benefit pension obligations.

3. Investment risk: Variations in the actual return from the scheme’s investments could affect the scheme’s ability to meet its future pension obligations.

Results   2017     2016  
£000's £000's £000's £000's
 
Assets at start of year 2,715 2,985
Defined benefit obligation at start of year (2,431) (2,782)
Net asset at 1 April 284 203
 
Expected return on assets 95 95
Interest cost (85) (89)
10 6
 
(Loss) on asset return (165) (42)
Experience (loss)/gain (300) 13
Loss/(Gain) on changes in assumptions (18) 56
Statement of other comprehensive income (483) 27
 
Employer contributions gross 76 55
Expenses paid by trustees (8) (7)
68 48
Net (liability)/asset at 31 March 2017 (121) 284
 
Actual assets at end of year 2,314 2,715
Actual defined benefit obligation at end of year (2,435) (2,431)
 

The pension fund assets are all held within a policy managed by an insurance company.

Reconciliation of changes in the asset value during the year

  2017     2016  
£000's £000's £000's £000's
 
Fair value of assets at 1 April 2,715 2,985
Expected return on assets 95 95
(Loss) on asset return (165) (42)
Employer contributions (gross) 76 55
Expenses paid by trustees (8) (7)
(Decrease) in secured pensioners' value due to scheme experience (247) (371)
Benefits paid (152) -

Fair value of assets at 31 March 2016

2,314 2,715
 
Reconciliation of changes in the liability value during the year
 
Defined benefit obligation at 1 April 2,431 2,782
Interest cost 85 89
Experience loss/(gain) on liabilities 300 (13)
Loss on changes in assumptions 18 (56)
(Decrease) in secured pensioners' value due to scheme experience (247) (371)
Benefits paid (152) -
Defined benefit obligation at 31 March 2016 2,435 2,431
 

The expected contribution to be paid by the employer during the next accounting year is £59,000.

Year ended 31 March   2017   2016   2015   2014   2013
£000's £000's £000's £000's £000's
 
Fair value of plan assets 2,314 2,715 2,985 2,680 2,760
Present value of defined benefit obligation 2,435 2,431 2,782 2,478 2,631
(Deficit)/Surplus in plan (121) 284 203 202 129

Experience (losses)/gains on plan liabilities

(300) 13 2 4 (31)

Defined benefit obligation – sensitivity analysis

The following amounts are the effect (on the defined benefit obligation) of reasonably possible changes to the key actuarial assumptions, as required by IAS 19.

Actuarial assumption   Reasonably   (Decrease)/Increase in Defined Benefit

Possible Change

Obligation
2017   £000's   2016   £000's
Discount rate (+/- 1%) (25) 30 (107) 138
Members' life expectancy (+/- 1year) 7 (7) 26 (27)
 

The company has given a floating charge dated 1 December 2006 over all of its assets to the trustees of the pension fund to secure all present and future obligations and liabilities to the pension fund.

22. Share-based payments

The measurement requirements of IFRS2 have been implemented in respect of share options that were granted after 7 November 2002. The expense recognised for share based payments made during the year is shown in the following table:

  2017   2016
£000's £000's
 
Total expense arising from equity settled share-based transactions 678 356
 

The share based payment plans are described below:

Movements in issued share options and jointly owned shares during the year

The following table illustrates the number and weighted average exercise prices (WAEP) of and movements in, share options and jointly owned shares during the period:

  Options     Jointly owned   Options   Jointly owned    
shares shares
2017 2017 2017   2017 2016   2016 2016   2016
000's WAEP 000's WAEP 000's WAEP 000's WAEP
£ £ £ £
 
Outstanding at 1 April 5,694 2.41 552 2.05 3,642 1.82 2,603 2.00
Granted during the period 1,272 4.35 - - 3,029 2.83 - -
Expired/cancelled during the period (41) 2.37 - - (29) 1.95 - -
Exercised during the period (1,332) 1.94 (552) 2.05 (948) 1.52 (2,051) 1.99
 
Outstanding at 31 March 5,593 2.96 - - 5,694 2.41 552 2.05
Exercisable at 31 March 474   1.84   -   -   836   1.79   552   2.05
 

The average share price during the year was 456.85p (2016: 294.62p).

The maximum aggregate number of shares over which options may currently be granted cannot exceed 10 per cent of the nominal share capital of the Company on the grant date. The options outstanding at 31 March 2017 had a weighted average share price of £2.96 (2016: £2.41) and a weighted average contractual life of 5.6 years (2016: 5.7 years).

Eco Animal Health Group plc Executive Share Option Scheme

In accordance with the Executive Share Option Scheme, approved and unapproved share options are granted to directors and employees who devote at least 25 hours per week to the performance of duties or employment with the Company.

Details of options granted to directors can be found in the Directors Report and notes 29 (Directors Emoluments) and 31 (Related Party Transactions).

The exercise price of the options is equal to the market price of the shares at the date of grant. The options vest three years from the date of grant and if the option holder ceases to be a director or employee of the Company due to injury, disability, redundancy or retirement on reaching pensionable age or any other age at which they are bound to retire at in accordance with the terms of their contract of employment, the option may be exercised within a period of six months after the option holders so ceasing, although the Board may, at its discretion, extend this period by up to 36 months after the date of cessation.

If the option holder ceases employment for any other reason, the option may not be exercised unless the Board permits. The approved and unapproved options will be forfeited where they remain unexercised at the end of their respective contractual lives of ten and seven years.

An analysis of the expiry dates of the outstanding options is given below:

Date of grant   Unapproved   Approved   Exercise price (pence)   Expiry date
 
03 March 2008 34,410 108.50 03 March 2018
06 August 2009 22,000 135.00 06 August 2019
11 October 2011 25,300 186.50 11 October 2021
11 October 2011 95,000 186.50 11 October 2018
09 July 2012 175,000 222.50 09 July 2018
09 October 2013 47,040 196.00 09 October 2023
09 October 2013 74,960 196.00 09 October 2020
07 August 2014 76,300 161.50 07 August 2024
07 August 2014 174,200 161.50 07 August 2021
13 February 2015 113,800 200.50 13 February 2025
13 February 2015 474,200 200.50 13 February 2022
16 April 2015 4,000 239.00 16 April 2025
16 April 2015 41,000 239.00 16 April 2022
26 August 2015 135,650 265.00 26 August 2025
26 August 2015 1,680,350 265.00 26 August 2022
18 December 2015 700,000 312.50 18 December 2022
18 January 2016 10,200 315.00 18 January 2026
18 January 2016 362,800 315.00 18 January 2023
17 February 2016 24,600 312.50 17 February 2026
17 February 2016 400 312.50 17 February 2023
01 March 2016 9,600 312.50 01 March 2026
01 March 2016 40,400 312.50 01 March 2023
12 September 2016 26,950 432.50 12 September 2026
12 September 2016 445,050 432.50 12 September 2023
15 September 2016 12,750 435.00 15 September 2026
15 September 2016 777,250 435.00 15 September 2023
11 October 2016 6,000 492.50 11 October 2026
11 October 2016 4,000 492.50 11 October 2023
     
5,044,610   548,600
 

ECO Animal Health Group plc Joint Share Ownership Plan

The shares are awarded at the market price on the day of the award and are held jointly by the employee concerned and the ECO Animal Health Group plc Employee Benefit Trust. After a three year vesting period, the shares may be sold at the option of the employee. The proceeds of sale are split between the trust and the employee so that the Trust receives the original market value of the shares sold plus a 5.9% per annum carry charge, with the employee receiving any excess over this amount.

Because these are actual issued shares in the company rather than options there is no expiry date associated with jointly owned shares. However, they will normally be forfeit if the employee ceases to be an employee of the company for any reason other than death, injury, redundancy, retirement on or after normal retirement age or disposal by the Group of the employing business entity.

The market price of the shares at 31 March 2017 was 500.0p with a range in the year of 340.0p to 517.5p.

No shares were issued under the Joint Share Ownership Plan during the year or the previous year and no shares are currently held under the terms of the plan.

Inputs to the Valuation Model (for options and jointly owned shares)

The fair value of share options granted prior to 31 March 2007 were estimated at the time of grant using trinomial pricing model, taking into account all the terms and conditions upon which the options were granted. For options issued after 1 April 2007, the directors took the decision that a Black-Scholes model would be more appropriate.

The following table lists the inputs to the Black-Scholes model which applies to both options and jointly owned shares.

  2017   2016   2015   2014   2013
 
Vesting period (years) 3 3 3 3 3
Option expiry (years) 7-10 yrs 7-10 yrs 7-10 yrs 7-10 yrs 7-10 yrs
Dividends expected on the shares 1.50% 1.50% 2.0-2.3% 1.4-1.9% 1.40%
Risk free rate (average) 1.00% 1.00% 1.00% 0.5-1.2% 0.50%
Volatility of share price 20% 20% 15% 20% 25%
Weighted average fair value 61.4 43.0 19.2 29.1 38.7
(pence)
 

The risk free rate has been based on the yield from UK Government treasury coupons. The volatility of the share price was estimated based on standard deviation calculations on the historic share price.

The fair value of the part interest in the jointly owned shares was calculated using a Black-Scholes model with the same assumptions as those used for the options issued during the same year.

23. Share capital

  2017   2016
£000's £000's
Authorised
68,100,000 Ordinary shares of 5p each 3,405 3,405
10,790 Deferred ordinary shares of 10p each 1 1
32,334 Convertible preference shares of £1 each 32   32
3,438   3,438
 
Allotted, called up and fully paid
65,422,706 (2016: 64,090,446) Ordinary shares of 5p each 3,271 3,205
 

During the year the Company sold 24,311 of its own shares out of treasury at an average price of £4.39, realising a gain of £47,000 which has been credited to share premium.

During the year 1,332,260 shares were issued at a premium of £2,516,000 as a result of the exercise of options by employees. (2016: 948,025 shares at a premium of £1,392,000).

24. Non-controlling (minority) interests

  2017   2017   2016   2016
£000's £000's £000's £000's
 
Balance at 1 April 3,202 3,029
Share of subsidiary's profit for the year 1,434 672
Share of foreign exchange gain/(loss) on net investment 293 (97)
1,727 575
Share of dividend paid by subsidiary (587) (402)
 
Balance at 31 March 4,342 3,202
 

25. Treasury share reserve

  2017   2016
£000's £000's
 
Balance at 1 April 1,144 5,217
Repaid on disposal of jointly owned shares 1,134 4,073
Balance written off to income statement 10   -
Balance at 31 March -   1,144
 

Treasury share reserve consisted of £1,144,000, being the cost of 552,360 shares in the Company held by the Group’s JSOP. These shares were sold during the year and the cost was repaid to the group.

26. Other reserves

Group and Company   Capital redemption   Reserve   Total
reserve for share-
based
payments
£000's £000's £000's
 
At 31 March 2015 106 1,669 1,775
Share-based payments - 326 326
Transfer to retained earnings on expiry of options -   (73)   (73)
At 1 April 2016 106 1,922 2,028
Share-based payments - 678 678
Transfer to retained earnings on expiry of options -   (257)   (257)
At 31 March 2017 106   2,343   2,449
 

The only material other reserve remaining at the year end is the reserve for share based payments which records the total amount which has been charged to the Group’s results in respect of unexpired share based payment arrangements.

Included in the Group’s retained earnings are the following exchange movements which have been taken directly to reserves on consolidation of the subsidiaries and joint operation listed below:

27. Financial commitments

At 31 March 2017 the Group had minimum commitments under non-cancellable operating leases as follows:

  Land and Buildings   Other  
2017   2016 2017 2016
£000's £000's £000's £000's
Expiry date:
Within one year 489 462 72 84
Between the second and fifth year 986 764 105 102
In over five years 2,285   1,777   -   -
3,760   3,003   177   186
 
Minimum expected sublease rental receipts:
Within one year 53 140 - -
Between two and five years -   53   -   -
53   193   -   -
 

28. Capital commitments

The group had no authorised capital commitments as at 31 March 2017 (2016: Nil).

29. Directors’ emoluments

  2017   2016
£000's £000's
 
Emoluments for qualifying services 846 569
Company pension contributions to money purchase schemes 22 187
Share-based payments 385 204
Benefits in kind 26   24
1,279   984
 

During the year the directors exercised 706,060 (2016: 27,640) share options realising a gain of £1,827,000 (2016: £50,000) and disposed of interests in 487,360 shares (2016: 1,956,930 shares) held under the joint share ownership plan realising gains of £1,044,000 (2016: £1,952,000).

The number of directors for whom retirement benefits are accruing under money purchase pension schemes amounted to 4 (2016: 4). No directors accrued benefits under defined benefit schemes for this or the previous year.

The highest paid director received £578,000 (2016: £412,000) including £174,000 (2016: £86,000) of share-based payments and £10,000 (2016: £80,000) of pension contributions.

30. Employees

Number of employees

The average number of employees (including directors) during the year was:

  2017   2016
Number Number
 
Directors 7 7
Production and development 65 64
Administration 41 42
Sales 88   85
 
201 198
     
 
Employment costs (including amounts capitalised)
2017 2016
£000's £000's
 
Wages and salaries 9,171 6,902
Share-based payments 678 326
Social security costs 749 641
Other pension costs 281   456
 
10,879   8,325
 

31 Post balance sheet event

The Company paid a dividend of £1,635,000 on 7h April 2017.

Eco Animal Health Group Plc

Source: Eco Animal Health Group Plc


Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Final Results - RNS